All In Biotech

Drug Trial Radar · NCT04777396

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,840

Actual

Start

May 18, 2021

Primary completion

Sep 16, 2025

Study completion Jan 30, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.

Conditions

  • Early Alzheimer's Disease

Interventions

  • SemagludtideDrug

    Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks

  • Placebo (semaglutide)Drug

    Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) scoreTime frame: From baseline (week 0) to week 104

Locations

447 sites in 37 countries. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute

    Phoenix, Arizona

  • Imaging Endpoints

    Scottsdale, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Tucson Neuroscience Research

    Tucson, Arizona

  • Advanced Research Center, Inc.

    Anaheim, California

  • Fullerton Neurology and Headache Center

    Fullerton, California

  • Pacific Research Network

    Lemon Grove, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • ASCLEPES Research Centers,

    Long Beach, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UCLA_Los Angeles

    Los Angeles, California

  • Wr-Pri, Llc

    Newport Beach, California

  • Well Care Medical Center

    Panorama City, California

  • Cedars-Sinai Medical Center

    Pasadena, California

  • Sharp Neurocog Res Ctr

    San Diego, California

  • Syrentis Clinical Research

    Santa Ana, California

  • Calfornia Neurosc Resrch Med

    Sherman Oaks, California

  • Southern California Research LLC

    Simi Valley, California

  • Mountain Neurological Research Center, Inc.

    Basalt, Colorado

  • Denver Neurological Research

    Denver, Colorado

  • Mile High Research Center

    Denver, Colorado

  • Yale University

    Fairfield, Connecticut

  • Topaz Clinical Research

    Apopka, Florida

  • JEM Research Institute

    Atlantis, Florida

  • Visionary Investigators Network

    Aventura, Florida

  • K2 Medical Research - Winter Garden

    Clermont, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Integrity Clinical Research, LLC

    Doral, Florida

  • Neuropsychiatric Research Cent

    Fort Myers, Florida

  • Finlay Medical Research Group

    Greenacres City, Florida

  • Indago Research & Health Center Inc.

    Hialeah, Florida

  • Hlth Cr Family Rehab & Res Ctr

    Hialeah, Florida

  • Galiz Research

    Hialeah, Florida

  • K2 The Villages

    Lady Lake, Florida

  • K2 Medical Research, Maitland

    Maitland, Florida

  • Hlth Cr Family Rehab & Res Ctr

    Miami, Florida

  • Premier Clin Res Inst, Inc.

    Miami, Florida

  • Premier Clinical Research Institute, Inc.

    Miami, Florida

  • Central Miami Medical Institute

    Miami, Florida

  • Novel Clinical Research Center, LLC

    Miami, Florida

Showing 40 of 447 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.